Clovis Oncology Revenue and Competitors
Estimated Revenue & Valuation
- Clovis Oncology's estimated annual revenue is currently $156.1M per year.
- Clovis Oncology received $445.0M in venture funding in April 2018.
- Clovis Oncology's estimated revenue per employee is $309,089
- Clovis Oncology's total funding is $145M.
- Clovis Oncology's current valuation is $352.2M. (January 2022)
- Clovis Oncology has 505 Employees.
- Clovis Oncology grew their employee count by -5% last year.
Clovis Oncology Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Clovis Oncology?
We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, companion diagnostics intended to direct a compound in development to the population that is most likely to benefit from its use. Our first commercial product and lead product candidate, Rubraca® (rucaparib) tablets, is an oral, small molecule poly ADP-ribose polymerase, or PARP, inhibitor of PARP1, PARP2 and PARP3. Studies open for enrollment or under consideration include ovarian, prostate, breast, gastroesophageal, pancreatic, lung and bladder cancers. Clovis holds worldwide rights for Rubraca. In the United States, Rubraca is approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Rubraca is also approved in the United States for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Rubraca is an unlicensed medical product outside of the U.S. In addition, we have two other product candidates: lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3, and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR). We maintain certain development and commercialization rights for lucitanib and global development and commercialization rights for rociletinib.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Clovis Oncology News
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting. Thu, April 28, 2022, 5:00 AM ·16 min read.
Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release. Zacks Equity Research. Wed, April 27, 2022, 12:03...
Early on Thursday, Clovis Oncology trumpeted positive Phase III data for their PARP player Rubraca in frontline maintenance care of ovarian...
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in Switzerland. The Swiss authority responsible for the authorization and supervision of therapeutic products (Swissmedic)i gave a positive recommendation for Rubraca as maintenance trea ...
BOULDER, Colo.--(BUSINESS WIRE)--Mar 19, 2021-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca ® (rucaparib) will take place today in an oral presentation at the Society of Gynecologic Oncology Virtual Annu ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Clovis Oncology Funding
|2015-07-13||$Undisclosed||Undisclosed||J. P. Morgan Securities LLC||Article|
|2017-01-04||$175.0M||Undisclosed||J. P. Morgan Securities LLC||Article|
|2017-06-21||$250.0M||Undisclosed||J. P. Morgan Securities LLC||Article|
|2018-04-17||$445.0M||Undisclosed||J. P. Morgan Securities LLC||Article|